Should You Buy InMode Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, InMode Ltd. (INMD) scores a robust 8.5/10 on our 32-signal Quality of Company framework. At the current market price of $14.87 and a $856M market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 8 of 12 CirclFi valuation models project upside for InMode Ltd. (INMD) at $14.87 — the model consensus leans bullish, with a Quality Score of 8.5/10 and Value-Trap risk of 21/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for InMode Ltd. (INMD) in 2026?
What Is the Bull Case vs the Bear Case for InMode Ltd. (INMD)?
| Bull case — $30.05 target (+102.1%) | Bear case — $8.11 target (-45.4%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, InMode Ltd.'s quality score of 8.5/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $8.11 (-45.4%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $14.87 and the median fair value of $19.72 implies +32.6% upside potential. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +147.5% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $30.05 (+102.1%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | Industry headwind: generic/biosimilar competition represents a meaningful risk for InMode Ltd. and its Medical Devices peers. |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for InMode Ltd.'s revenue and margin trajectory in the Medical Devices space. |
How Does INMD Compare to Its Medical Devices Peers?
Valuation data pages: SNN · CNMD · EW · XTNT · ESMC · ZBH · SENS · OWLT · CSDX · IRMD · PODD
Which Other Stocks Score Like INMD on Quality?
Closest companies to INMD’s Quality of Company score of 8.5/10, across all industries.
- PLXS — Plexus Corp. (QOC 8.5) · analysis
- CAKE — The Cheesecake Factory Incorporated (QOC 8.5) · analysis
- FCFS — FirstCash Holdings, Inc. (QOC 8.5) · analysis
- UMBF — UMB Financial Corporation (QOC 8.5) · analysis
- PFHO — Pacific Health Care Organization, Inc. (QOC 8.5) · analysis
- ONON — On Holding AG (QOC 8.5) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does INMD Appear In?
So Is InMode Ltd. (INMD) Worth Buying in 2026?
InMode Ltd. leans positive in our analysis — 8/12 models bullish, median fair value of $19.72 vs. $14.87, QOC 8.5/10. The case is constructive but not overwhelming, and the 4 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. InMode Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About INMD Stock?
Should I buy INMD stock right now?
Based on CirclFi's multi-model analysis, 8 of 12 models see upside for INMD at $14.87. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.5/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in InMode Ltd.?
Key risks include: wide model disagreement (270% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does INMD compare to its competitors?
Among Medical Devices peers, INMD holds a Quality Score of 8.5/10. Comparable companies include SNN (QOC 8.6), CNMD (QOC 8.5), EW (QOC 8.7). The relative ranking helps investors identify whether INMD offers better fundamental quality than alternatives in the same sector.
Is INMD a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. INMD's Quality Score of 8.5/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy INMD at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $8.11 to $30.05. At $14.87, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for INMD.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad